scPharmaceuticals Inc. (SCPH)

Market Cap	162.24M
Revenue (ttm)	13.59M
Net Income (ttm)	-54.81M
Shares Out	36.05M
EPS (ttm)	-1.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,653
Open	4.640
Previous Close	4.610
Day's Range	4.490 - 4.750
52-Week Range	4.250 - 12.750
Beta	0.05
Analysts	Strong Buy
Price Target	19.33 (+329.56%)
Earnings Date	May 8, 2024

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROS...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH

Analyst Forecast

According to 3 analysts, the average rating for SCPH stock is "Strong Buy." The 12-month stock price forecast is $19.33, which is an increase of 329.56% from the latest price.

Price Target

$19.33

(329.56% upside)

Analyst Consensus: Strong Buy